DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geary, R. S.
Right arrow Articles by Levin, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geary, R. S.
Right arrow Articles by Levin, A. A.

Vol. 25, Issue 11, 1272-1281, 1997

Pharmacokinetics and Metabolism in Mice of a Phosphorothioate Oligonucleotide Antisense Inhibitor of C-raf-1 Kinase Expression

Richard S. Geary, Janet M. Leeds, Jon Fitchett, Todd Burckin, Loanne Truong, Charles Spainhour, Moire Creek, and Arthur A. Levin

Isis Pharmaceuticals (R.S.G., J.M.L., J.F., T.B., L.T., A.A.L.), Chrysalis (C.S.), and SRI International (M.C.)

The plasma and tissue disposition of CGP 69846A (ISIS 5132) was characterized in male CD-1 mice following iv bolus injections administered every other day for 28 days (total of 15 doses). The doses ranged from 0.8 mg/kg to 100 mg/kg. Urinary excretion of oligonucleotide was also monitored over a 24-hr period following single dose administration over the same dose range. Pharmacokinetic plasma profiles were determined following single dose administration (dose 1) and after multiple doses (dose 15) at doses of 4 and 20 mg/kg. Concentrations in kidney, liver, spleen, heart, lung, and lymph nodes were characterized following doses 1, 8, and 15 for all doses. Capillary gel electrophoresis was used to quantitate intact (full-length) oligonucleotide and its metabolites (down to N - 11 base deletions) in both plasma and tissue at all time points. The plasma and tissue disposition of CGP 69846A was characterized by a rapid distribution into all tissues analyzed. Rapid plasma clearance of the parent oligonucleotide (9.3-14.3 ml/min/kg) was predominantly the result of distribution to tissue and, to a lesser extent, metabolism. Appearance and pattern of chain-shortened metabolites seen in plasma and tissue were consistent with predominantly exonuclease-mediated base deletion. No measurable accumulation of oligonucleotide was observed in plasma following multiple-dose administration, but both the liver and the kidney exhibited 2-3-fold accumulations. In general, the tissues exhibited half-lives for the elimination of parent oligonucleotide of 16-60 hr compared with plasma half-lives of 30-45 min. After repeated administrations, significant decreases in plasma clearance and volume of distribution at steady state (Vss) were observed following dose 15 at the dose of 20 mg/kg but not at the dose of 4 mg/kg. Changes in tissue accumulation and evidence for saturation of tissue distribution at the high doses may explain the plasma disposition changes observed in the absence of alteration of metabolism or plasma accumulation. Urinary excretion was a minor pathway for elimination of oligonucleotide over the 24-hr period immediately following iv administration. However, the amount of oligonucleotide excreted in the urine increased as a function of dose from less than 1% to approximately 13% of the administered dose over a dose range of 0.8 mg/kg to 100 mg/kg.

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Bourquin, D. Anz, K. Zwiorek, A.-L. Lanz, S. Fuchs, S. Weigel, C. Wurzenberger, P. von der Borch, M. Golic, S. Moder, et al.
Targeting CpG Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immunity
J. Immunol., September 1, 2008; 181(5): 2990 - 2998.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. Z. Yu, T.-W. Kim, A. Hong, T. A. Watanabe, H. J. Gaus, and R. S. Geary
Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100
Drug Metab. Dispos., March 1, 2007; 35(3): 460 - 468.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Beeram, A. Patnaik, and E. K. Rowinsky
Raf: A Strategic Target for Therapeutic Development Against Cancer
J. Clin. Oncol., September 20, 2005; 23(27): 6771 - 6790.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. Duan, J. H. P. Chan, K. McKay, J. R. Crosby, H. H. Choo, B. P. Leung, J. G. Karras, and W. S. F. Wong
Inhaled p38{alpha} Mitogen-activated Protein Kinase Antisense Oligonucleotide Attenuates Asthma in Mice
Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 571 - 578.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Wu, W. F. Lima, H. Zhang, A. Fan, H. Sun, and S. T. Crooke
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
J. Biol. Chem., April 23, 2004; 279(17): 17181 - 17189.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. S. Geary, R. Z. Yu, T. Watanabe, S. P. Henry, G. E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, and A. A. Levin
PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-{alpha} PHOSPHOROTHIOATE 2'-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES
Drug Metab. Dispos., November 1, 2003; 31(11): 1419 - 1428.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. P. Henry, R. C. Miner, W. L. Drew, J. Fitchett, C. York-Defalco, L. M. Rapp, and A. A. Levin
Antiviral Activity and Ocular Kinetics of Antisense Oligonucleotides Designed to Inhibit CMV Replication
Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2646 - 2651.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan, and A. A. Levin
Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 890 - 897.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. S. Geary, O. Khatsenko, K. Bunker, R. Crooke, M. Moore, T. Burckin, L. Truong, H. Sasmor, and A. A. Levin
Absolute Bioavailability of 2'-O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides following Intraduodenal Instillation in Rats
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 898 - 904.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Henry, K. Stecker, D. Brooks, D. Monteith, B. Conklin, and C. F. Bennett
Chemically Modified Oligonucleotides Exhibit Decreased Immune Stimulation in Mice
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 468 - 479.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Butler, R. M. Crooke, M. J. Graham, K. M. Lemonidis, M. Lougheed, S. F. Murray, D. Witchell, U. Steinbrecher, and C. F. Bennett
Phosphorothioate Oligodeoxynucleotides Distribute Similarly in Class A Scavenger Receptor Knockout and Wild-Type Mice
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 489 - 496.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. M. Crooke, M. J. Graham, M. J. Martin, K. M. Lemonidis, T. Wyrzykiewiecz, and L. L. Cummins
Metabolism of Antisense Oligonucleotides in Rat Liver Homogenates
J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 140 - 149.
[Abstract] [Full Text]

Home page
 Toxicol PatholHome page
D. K. Monteith and A. A. Levin
Synthetic Oligonucleotides: The Development of Antisense Therapeutics
Toxicol Pathol, January 1, 1999; 27(1): 8 - 13.
[Abstract] [PDF]

Home page
 Toxicol PatholHome page
S. P. Henry, M. V. Templin, N. Gillett, J. Rojko, and A. A. Levin
Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1
Toxicol Pathol, January 1, 1999; 27(1): 95 - 100.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Graham, S. T. Crooke, D. K. Monteith, S. R. Cooper, K. M. Lemonidis, K. K. Stecker, M. J. Martin, and R. M. Crooke
In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 447 - 458.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.